Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
The Danish company’s amylin analog looks like a match for GLP-1 agonists on efficacy, and better on tolerability, and is now moving quickly into Phase II.
In this podcast, glean insights from an experienced regulatory leader at Allucent and an expert currently navigating the complexities of the pre-IND stage at Ridgeline Therapeutics. They dive into best practices for pre-IND meetings and IND applications, helping you develop strategies to succeed in this increasingly challenging environment.
Discover what’s on the horizon for the pharma industry as truly transformative technologies revolutionize the way drugs are developed, delivered and manufactured.
A new podcast series marking 20 years of the Scrip Awards and their recognition of biopharma sector innovation.
Stay current with trends in infectious disease clinical trials, with fresh insights from a recent roundtable event. Discover how the landscape is evolving and what to expect in the future, with key takeaways from industry experts.
The ALS treatment Relyvrio was removed from the market as expected following a Phase III trial failure.
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.
Read the article to learn more about how fostering a culture of competence and fairness is allowing CF Pharma to deliver on its API and CMO capabilities.
In this week's podcast edition of Five Must-Know Things podcast: US Medicare price negotiations get soft landing; Medicare negotiations and patent cliff acceleration; Novo Nordisk steps into heart failure; PCSK9s and the convenience battle; and an investor’s view of Korean biotech potential.
Long-awaited list has a couple of surprises that are expected to face biosimilar competition either before negotiated prices are implemented in 2026 or during that year.
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.
Higher-dose mazdutide showed superiority over placebo after 24 weeks of treatment in a Phase II trial in Chinese adults with obesity. The potential best-in-class efficacy profile of the Lilly-originated GLP-1 receptor agonist is expected to help it gain the upper hand in the race for the leadership of the country's obesity market, estimated at $5.5bn in 2030.
The advantages of decentralized clinical trials (DCTs) are well recognized. COVID-19 showed that the DCT model was not only viable but practicable as a means of overcoming physical constraints on patient access to trial sites.
Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally.
It was a real pleasure to host the 18th Annual Scrip Awards and celebrate the many achievements of the pharmaceutical, biotechnology, clinical research and allied industries over the past year